Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
- Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
- Braftovi® (encorafinib) + Mektovi® (binimetinib): BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
- Duchenne Muscular Dystrophy Gene Therapy
- fidanacogene elaparvovec (Gene Therapy, coagulation factor IX): Hemophilia
- giroctocogene fitelparvovec (Gene Therapy, coagulation factor VIII): Hemophilia
- Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
- Prophylactic Vaccine: Clostridioides difficile Infection
- Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal)
- Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata
- Talzenna® (talazoparib): Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
- Xeljanz® (tofacitinib): Ankylosing Spondylitis
- Xtandi® (enzalutamide): Metastatic Castration Sensitive Prostate Cancer, Non-Metastatic High-Risk Castration Sensitive Prostate Cancer
Pipeline Snapshot as of October 27, 2020
- Discovery Projects
- 29Phase 1
- 36Phase 2
- 21Phase 3
- 6Registration
- Total92
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Primary clostridioides difficile infection (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (pediatric) (BREAKTHROUGH, FAST TRACK) | Phase 3 | Product Enhancement | Vaccine |
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (adult) (BREAKTHROUGH, FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive Group B Streptococcus Infection (maternal) | Phase 2 | New Molecular Entity | Vaccine |
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (infants and children) | Phase 2 | New Molecular Entity | Vaccine |
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Serogroups ABCWY Meningococcal Infections (adolescent and young adults) | Phase 3 | New Molecular Entity | Vaccine |
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Respiratory Syncytial Virus Infection (maternal) (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-07302048 (BNT162) Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in partnership with BioNTech) (FAST TRACK) (Pivotal Phase 2/3 global study) | Phase 3 | New Molecular Entity | Vaccine |
PF-07307405 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Lyme disease | Phase 2 | New Molecular Entity | Vaccine |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Urothelial Cancer (Biologic) (E.U.) | Registration | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Merkel Cell Carcinoma (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/CMP-001 for Head and Neck Cancer | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/ Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic) | Phase 1 | Product Enhancement | Biologic |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | BRAF-mutant Metastatic Melanoma Brain Metastasis (ORPHAN - U.S.) | Phase 2 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | 1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer | Phase 2 | Product Enhancement | Small Molecule |
